Introduction Portal hypertension (PH) drives the progression of liver cirrhosis to
decompensation and death. Hepatic venous pressure gradient (HVPG) measurement is the …

Background and Aims A reduction in hepatic venous pressure gradient (HVPG) is the most
accurate marker for assessing the severity of portal hypertension and the effectiveness of …

Background & Aims In individuals with compensated advanced chronic liver disease
(cACLD), the severity of portal hypertension (PH) determines the risk of decompensation …

In patients with chronic liver disease, portal hypertension is driven by progressive fibrosis
and intrahepatic vasoconstriction. Interruption of the initiating and perpetuating etiology …

Abstract Background & Aims Metabolic dysfunction-associated steatotic liver disease
(MASLD) is a leading cause of advanced chronic liver disease (ACLD). Portal hypertension …

Background Portal hypertension (PHT) presents a challenging issue of liver cirrhosis. This
study aims to identify novel biomarkers for severe PHT (SPHT) and explore the …

Background & Aims Distinct prognostic stages of advanced chronic liver disease (ACLD) are
defined by severity of portal hypertension (PH) and the presence/absence of clinical …

Background Idiopathic non‐cirrhotic portal hypertension (INCPH) is a rare life‐threatening
liver disease that lacks a specific diagnostic test being frequently misdiagnosed as …

OBJECTIVES: Idiopathic portal hypertension (IPH) is a rare cause of portal hypertension that
lacks a specific diagnostic test. Requiring ruling-out other causes of portal hypertension it is …

The comprehensive management of chronic liver disease and subsequent portal
hypertension (PH) remains a challenge in clinical treatment. The consequences of PH are …